PMID- 27142582
OWN - NLM
STAT- MEDLINE
DCOM- 20170227
LR  - 20170227
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 15
IP  - 8
DP  - 2016 Aug
TI  - Safety of available treatment options for renal cell carcinoma.
PG  - 1097-106
LID - 10.1080/14740338.2016.1184643 [doi]
AB  - INTRODUCTION: For many years, cytokines (high-dose interleukin (IL)-2 and 
      interferon (IFN)) have been the unique available treatment options for metastatic 
      renal cell carcinoma (mRCC) and they provided durable but modest responses at the 
      cost of significant toxicities. To date, targeted therapies have replaced 
      cytokine therapy due to higher response rates and more favorable toxicity 
      profiles. The major classes of targeted therapy for mRCC include tyrosine kinase 
      inhibitors, monoclonal antibody against vascular endothelial grow factors and 
      inhibitors of the mammalian target of rapamycin. Thanks to these new strategies, 
      the prognosis for the mRCC is shifting toward a chronic disease and the new 
      challenges are the adequate treatment of adverse events (AEs) and the care for 
      quality of life, which is crucial. Emerging immunotherapies targeting the 
      programmed death-1 (PD-1) receptor and the programmed death ligand-1 (PD-L1) 
      ligand have shown promising results in both efficacy and safety profiles. AREAS 
      COVERED: Safety data published on available treatment options for renal cell 
      carcinoma RCC are reviewed. EXPERT OPINION: Various toxicities are associated 
      with targeted agents; these toxicities are generally well tolerated but careful 
      monitoring and appropriate management are needed to optimize the use of these 
      strategies.
FAU - Derosa, Lisa
AU  - Derosa L
AD  - a Gustave Roussy Cancer Campus.
FAU - Albiges, Laurence
AU  - Albiges L
AD  - a Gustave Roussy Cancer Campus.
FAU - Massard, Christophe
AU  - Massard C
AD  - a Gustave Roussy Cancer Campus.
FAU - Loriot, Yohann
AU  - Loriot Y
AD  - a Gustave Roussy Cancer Campus.
FAU - Fizazi, Karim
AU  - Fizazi K
AD  - a Gustave Roussy Cancer Campus.
FAU - Escudier, Bernard
AU  - Escudier B
AD  - a Gustave Roussy Cancer Campus.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160523
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cytokines)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Cytokines/administration & dosage/pharmacology/therapeutic use
MH  - Drug Monitoring/methods
MH  - Humans
MH  - Immunotherapy/adverse effects/methods
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Molecular Targeted Therapy
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - Quality of Life
OTO - NOTNLM
OT  - Renal cell carcinoma
OT  - checkpoint inhibitors
OT  - immunotherapies
OT  - mammalian target of rapamycin
OT  - targeted therapy
OT  - vascular endothelial growth factor
EDAT- 2016/05/05 06:00
MHDA- 2017/02/28 06:00
CRDT- 2016/05/05 06:00
PHST- 2016/05/05 06:00 [entrez]
PHST- 2016/05/05 06:00 [pubmed]
PHST- 2017/02/28 06:00 [medline]
AID - 10.1080/14740338.2016.1184643 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2016 Aug;15(8):1097-106. doi: 
      10.1080/14740338.2016.1184643. Epub 2016 May 23.